Answers are grounded in this paper and cite their sources.
Evaluates post-transplant TKI effect on survival and GVHD in CML, suggesting survival benefits from TKI maintenance.
e18599 Background: Although tyrosine kinase inhibitors (TKIs) have reduced the need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia (CML), transplantation remains necessary for patients with TKI resistance, intolerance, or disease progression. Post-transplant TKI maintenance is widely used, yet real-world data evaluating its impact on overall survival (OS) and graft-versus-host disease (GVHD) are limited. We assessed the association between post-HSCT TKI use and long-term survival and GVHD outcomes. Methods: Adult CML patients undergoing allo-HSCT between January 2010 and June 2025 were identified in the TriNetX Research Network and categorized by TKI exposure within 3 months post-transplant. Cohorts were propensity score matched 1:1. OS was evaluated using Kaplan–Meier and Cox regression for 3 and 5 years. A landmark analysis beginning on day 30 was performed to address immortal time bias. Secondary outcomes included chronic GVHD within 1 year. Results: After matching, 350 patients were included (175 TKI vs 175 no TKI). At 3 years from transplant (day 0), OS was significantly higher with TKI therapy (72.67% vs 58.90%; HR 0.57, 95% CI 0.389–0.837; log-rank p=0.0036), with consistent landmark results (73.51% vs 59.93%; HR 0.566, 95% CI 0.383–0.838; p=0.0040). At 5 years, OS remained superior (68.75% vs 55.31%; HR 0.588, 95% CI 0.407–0.851; p=0.0043), with similar landmark findings (69.55% vs 56.27%; HR 0.585, 95% CI 0.402–0.853; p=0.0048). Chronic GVHD within 1 year was more frequent among TKI-treated patients (37.14% vs 24.57%; OR 1.81, 95% CI 1.14–2.88; p=0.011). Conclusions: Post-transplant TKI therapy was associated with significantly improved 3- and 5-year OS in patients with CML undergoing allo-HSCT, including landmark analysis. Higher rates of chronic GVHD may reflect confounding by indication and longer survival rather than a direct causal effect. These findings support post-HSCT TKI maintenance as an important survival-enhancing strategy in CML.
No takes yet. Share an insight, caveat, or question.
Bhinder et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: